Rajnish A. Gupta
Vanderbilt University Medical Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Rajnish A. Gupta.
Nature | 2010
Rajnish A. Gupta; Nilay R. Shah; Kevin C. Wang; Jeewon Kim; Hugo M. Horlings; David J. Wong; Miao-Chih Tsai; Tiffany Hung; Pedram Argani; John L. Rinn; Yulei Wang; Pius M. Brzoska; Benjamin Kong; Rui-Chun Li; Robert B. West; Marc J. van de Vijver; Saraswati Sukumar; Howard Y. Chang
Large intervening non-coding RNAs (lincRNAs) are pervasively transcribed in the genome yet their potential involvement in human disease is not well understood. Recent studies of dosage compensation, imprinting, and homeotic gene expression suggest that individual lincRNAs can function as the interface between DNA and specific chromatin remodelling activities. Here we show that lincRNAs in the HOX loci become systematically dysregulated during breast cancer progression. The lincRNA termed HOTAIR is increased in expression in primary breast tumours and metastases, and HOTAIR expression level in primary tumours is a powerful predictor of eventual metastasis and death. Enforced expression of HOTAIR in epithelial cancer cells induced genome-wide re-targeting of Polycomb repressive complex 2 (PRC2) to an occupancy pattern more resembling embryonic fibroblasts, leading to altered histone H3 lysine 27 methylation, gene expression, and increased cancer invasiveness and metastasis in a manner dependent on PRC2. Conversely, loss of HOTAIR can inhibit cancer invasiveness, particularly in cells that possess excessive PRC2 activity. These findings indicate that lincRNAs have active roles in modulating the cancer epigenome and may be important targets for cancer diagnosis and therapy.
Nature | 2011
Kevin C. Wang; Yul W. Yang; Bo Liu; Amartya Sanyal; Ryan Corces-Zimmerman; Yong Chen; Bryan R. Lajoie; Angeline Protacio; Ryan A. Flynn; Rajnish A. Gupta; Joanna Wysocka; Ming Lei; Job Dekker; Jill A. Helms; Howard Y. Chang
The genome is extensively transcribed into long intergenic noncoding RNAs (lincRNAs), many of which are implicated in gene silencing. Potential roles of lincRNAs in gene activation are much less understood. Development and homeostasis require coordinate regulation of neighbouring genes through a process termed locus control. Some locus control elements and enhancers transcribe lincRNAs, hinting at possible roles in long-range control. In vertebrates, 39 Hox genes, encoding homeodomain transcription factors critical for positional identity, are clustered in four chromosomal loci; the Hox genes are expressed in nested anterior-posterior and proximal-distal patterns colinear with their genomic position from 3′ to 5′of the cluster. Here we identify HOTTIP, a lincRNA transcribed from the 5′ tip of the HOXA locus that coordinates the activation of several 5′ HOXA genes in vivo. Chromosomal looping brings HOTTIP into close proximity to its target genes. HOTTIP RNA binds the adaptor protein WDR5 directly and targets WDR5/MLL complexes across HOXA, driving histone H3 lysine 4 trimethylation and gene transcription. Induced proximity is necessary and sufficient for HOTTIP RNA activation of its target genes. Thus, by serving as key intermediates that transmit information from higher order chromosomal looping into chromatin modifications, lincRNAs may organize chromatin domains to coordinate long-range gene activation.
Nature Reviews Cancer | 2001
Rajnish A. Gupta; Raymond N. DuBois
Population-based studies have established that long-term intake of non-steroidal anti-inflammatory drugs (NSAIDs), compounds that inhibit the enzymatic activity of cyclooxygenase (COX), reduces the relative risk for developing colorectal cancer. These studies led to the identification of a molecular target, COX-2, that is involved in tumour promotion during colorectal cancer progression. Recent studies in humans indicate that therapy with specific COX-2 inhibitors might be an effective approach to colorectal cancer prevention and treatment.
Gastroenterology | 1998
Jeffrey A. Brockman; Rajnish A. Gupta; Raymond N. DuBois
Abstract Background & Aims: Peroxisomal proliferator–activated receptor γ (PPARγ) is a nuclear hormone receptor that provides a direct link between fatty acid metabolism and control of gene transcription. The objective of this study was to determine the biological effect(s) of PPARγ activation in colorectal carcinoma cells. Methods: PPARγ expression and activity were measured in 4 human colon cancer cell lines using reverse-transcription polymerase chain reaction, immunoprecipitation and immunoblotting, and transient reporter gene assays. The effects of activated PPARγ in these cell lines were assessed in cellular proliferation and anchorage-independent growth assays. Flow cytometry was used to determine the effects of PPARγ activation on progression through the cell cycle. Results: PPARγ was expressed in all 4 colon cancer cell lines examined and was transcriptionally functional in 3 of the 4. Treatment of these cells with a selective PPARγ activator (BRL 49653) resulted in inhibition of anchorage-independent growth. The degree of growth inhibition correlated with the level of functional PPARγ present. Finally, activation of PPARγ resulted in G1 cell cycle arrest. Conclusions: Activation of the PPARγ pathway in colon cancer cells has potent antiproliferative effects, suggesting that this nuclear hormone receptor may provide a novel target for prevention and treatment of colorectal cancer in humans. GASTROENTEROLOGY 1998;115:1049-1055
Journal of Biological Chemistry | 2003
Takiko Daikoku; Hiromichi Matsumoto; Rajnish A. Gupta; Sanjoy K. Das; Max Gassmann; Raymond N. DuBois; Sudhansu K. Dey
Increased uterine vascular permeability and angiogenesis are hallmarks of implantation and placentation. These events are profoundly influenced by vascular endothelial growth factor (VEGF). We previously showed that VEGF isoforms and VEGF receptors are expressed in the uterus, suggesting the role of VEGF in uterine vascular permeability and angiogenesis required for implantation and decidualization. We have recently shown that estrogen promotes uterine vascular permeability but inhibits angiogenesis, whereas progesterone stimulates angiogenesis with little effect on vascular permeability. However, the mechanism of differential steroid hormonal regulation of uterine angiogenesis remains unresolved. Oxygen homeostasis is essential for cell survival and is primarily mediated by hypoxia-inducible factors (HIFs). These factors are intimately associated with vascular events and induce VEGF expression by binding to the hypoxia response element in the VEGF promoter. HIFα isoforms function by forming heterodimers with the aryl hydrocarbon nuclear translocator (ARNT) (HIF-β) family members. There is very limited information on the relationship among HIFs, ARNTs, and VEGF in the uterus during early pregnancy, although the role of HIFs in regulating VEGF and angiogenesis in cancers is well documented. Using molecular and physiological approaches, we here show that uterine expression of HIFs and ARNTs does not correlate with VEGF expression during the preimplantation period (days 1–4) in mice. In contrast, their expression follows the localization of uterine VEGF expression with increasing angiogenesis during the postimplantation period (days 5–8). This disparate pattern of uterine HIFs, ARNTs, and VEGF expression on days 1–4 of pregnancy suggests HIFs have multiple roles in addition to the regulation of angiogenesis during the peri-implantation period. Using pharmacological, molecular, and genetic approaches, we also observed that although progesterone primarily up-regulates uterine HIF-1α expression, estrogen transiently stimulates that of HIF-2α.
Nature Medicine | 2000
Rajnish A. Gupta; Raymond N. DuBois
Combination therapies involving inhibitors of the epidermal growth factor and cyclooxygenase signaling prevent colorectal adenomas in mice. This synergistic effect may be due to the convergance of these two signaling pathways (pages 1024–1028).
Annals of the New York Academy of Sciences | 2006
Rajnish A. Gupta; Raymond N. DuBois
Abstract: Inhibitors of the inducible cyclooxygenase (COX‐2) have emerged as a promising new class of drugs that may be useful for the prevention of colorectal cancer. Experimental evidence to support such a claim has come from both clinical and laboratory findings that show that both selective and nonselective COX inhibitors effectively block tumor growth. Although the precise mechanism(s) by which these drugs modulate tumor growth is not known, there is evidence from colon carcinoma cell culture studies that COX‐2 activity may play an important role in regulating angiogenesis and apoptosis. Recent data obtained in animal studies suggest that COX‐2 inhibitors may also be useful in the treatment of established colorectal tumors. Treatment of COX‐2 expressing tumor cells with selective COX‐2 inhibitors appears to reset the balance between cell proliferation and cell death such that there is no increase in tumor volume.
Cancer Research | 2013
Nilay Shah; Kideok Jin; Leigh Ann Cruz; Sunju Park; Helen Sadik; Soonweng Cho; Chirayu Goswami; Harikrishna Nakshatri; Rajnish A. Gupta; Howard Y. Chang; Zhe Zhang; Ashley Cimino-Mathews; Leslie Cope; Christopher B. Umbricht; Saraswati Sukumar
Most breast cancers expressing the estrogen receptor α (ERα) are treated successfully with the receptor antagonist tamoxifen (TAM), but many of these tumors recur. Elevated expression of the homeodomain transcription factor HOXB13 correlates with TAM-resistance in ERα-positive (ER+) breast cancer, but little is known regarding the underlying mechanism. Our comprehensive evaluation of HOX gene expression using tiling microarrays, with validation, showed that distant metastases from TAM-resistant patients also displayed high HOXB13 expression, suggesting a role for HOXB13 in tumor dissemination and survival. Here we show that HOXB13 confers TAM resistance by directly downregulating ERα transcription and protein expression. HOXB13 elevation promoted cell proliferation in vitro and growth of tumor xenografts in vivo. Mechanistic investigations showed that HOXB13 transcriptionally upregulated interleukin (IL)-6, activating the mTOR pathway via STAT3 phosphorylation to promote cell proliferation and fibroblast recruitment. Accordingly, mTOR inhibition suppressed fibroblast recruitment and proliferation of HOXB13-expressing ER+ breast cancer cells and tumor xenografts, alone or in combination with TAM. Taken together, our results establish a function for HOXB13 in TAM resistance through direct suppression of ERα and they identify the IL-6 pathways as mediator of disease progression and recurrence.
Genes & Development | 1999
Hyunjung Lim; Rajnish A. Gupta; Wen-ge Ma; Bibhash C. Paria; David E. Moller; Jason D. Morrow; Raymond N. DuBois; James M. Trzaskos; Sudhansu K. Dey
Carcinogenesis | 1998
Raymond N. DuBois; Rajnish A. Gupta; Jeffrey A. Brockman; Bandaru S. Reddy; Samuel L. Krakow; Mitchell A. Lazar